Effect of Alendronate Sodium Combined with Alpha-Calciferol on Chronic Obstructive Pulmonary Disease with Osteoporosis

IF 0.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Longqiang Guo, Degang Tao, Bing Chen, Hui Zhu, Fei Wang
{"title":"Effect of Alendronate Sodium Combined with Alpha-Calciferol on Chronic Obstructive Pulmonary Disease with Osteoporosis","authors":"Longqiang Guo, Degang Tao, Bing Chen, Hui Zhu, Fei Wang","doi":"10.36468/pharmaceutical-sciences.spl.676","DOIUrl":null,"url":null,"abstract":"We attempt to explore and study the effect of alendronate sodium combined with alpha-calciferol on chronic obstructive pulmonary disease patients with osteoporosis treatment and the changes of serum receptor activator for nuclear factor kappa B ligand and osteoprotegerin levels. We randomly selected 56 patients in the hospital from December 2021 to December 2022 as the study subjects. According to the time of admission, we divided them into two parts. 28 patients were given routine treatment as the control group and the other 28 patients were given alendronate sodium combined with alpha-calciferol as the observation group. Evaluate and compare both groups on the clinical efficacy rate and measure the serum receptor activator for nuclear factor kappa B ligand level and osteoprotegerin level after taking the fasting venous blood of the patients. The adverse reactions occurred during the treatment were counted and adverse reactions rate was calculated. The results showed that observation group had higher clinical control ratio and effective ratio than control group. In addition, observation group possessed higher clinical efficacy efficiency value of the patients than control group and the improvement was more obvious (p<0.05). In terms of serum level results, observation group had better data values of patients than control group. The serum receptor activator for nuclear factor kappa B ligand level, osteoprotegerin level, forced vital capacity 1 level and forced vital capacity 1/forced vital capacity values of patients in observation group were significantly improved than those in control group (p<0.05). In terms of adverse reaction evaluation, observation group during treatment had lower adverse reactions rate than control group (p<0.05). Alendronate sodium combined with alpha-calciferol can improve the clinical efficacy of chronic obstructive pulmonary disease and osteoporosis patients to a certain extent, and have a better effect on serum receptor activator for nuclear factor kappa B ligand, osteoprotegerin level and lung function.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36468/pharmaceutical-sciences.spl.676","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

We attempt to explore and study the effect of alendronate sodium combined with alpha-calciferol on chronic obstructive pulmonary disease patients with osteoporosis treatment and the changes of serum receptor activator for nuclear factor kappa B ligand and osteoprotegerin levels. We randomly selected 56 patients in the hospital from December 2021 to December 2022 as the study subjects. According to the time of admission, we divided them into two parts. 28 patients were given routine treatment as the control group and the other 28 patients were given alendronate sodium combined with alpha-calciferol as the observation group. Evaluate and compare both groups on the clinical efficacy rate and measure the serum receptor activator for nuclear factor kappa B ligand level and osteoprotegerin level after taking the fasting venous blood of the patients. The adverse reactions occurred during the treatment were counted and adverse reactions rate was calculated. The results showed that observation group had higher clinical control ratio and effective ratio than control group. In addition, observation group possessed higher clinical efficacy efficiency value of the patients than control group and the improvement was more obvious (p<0.05). In terms of serum level results, observation group had better data values of patients than control group. The serum receptor activator for nuclear factor kappa B ligand level, osteoprotegerin level, forced vital capacity 1 level and forced vital capacity 1/forced vital capacity values of patients in observation group were significantly improved than those in control group (p<0.05). In terms of adverse reaction evaluation, observation group during treatment had lower adverse reactions rate than control group (p<0.05). Alendronate sodium combined with alpha-calciferol can improve the clinical efficacy of chronic obstructive pulmonary disease and osteoporosis patients to a certain extent, and have a better effect on serum receptor activator for nuclear factor kappa B ligand, osteoprotegerin level and lung function.
阿仑膦酸钠联合α -钙化醇治疗慢性阻塞性肺疾病合并骨质疏松的疗效观察
我们试图探讨阿仑膦酸钠联合α -钙化醇对慢性阻塞性肺疾病合并骨质疏松治疗患者的影响及血清核因子κ B配体受体激活剂和骨保护素水平的变化。我们随机选取2021年12月至2022年12月在该院就诊的56例患者作为研究对象。根据入场时间,我们将他们分为两部分。28例患者给予常规治疗作为对照组,28例患者给予阿仑膦酸钠联合α -钙化醇治疗作为观察组。评价比较两组患者的临床有效率,取患者空腹静脉血后测定血清核因子κ B受体激活剂配体水平和骨保护素水平。统计治疗过程中不良反应发生情况,计算不良反应发生率。结果显示,观察组临床控制率和有效率均高于对照组。观察组患者的临床疗效效率值高于对照组,改善更明显(p<0.05)。在血清水平结果上,观察组患者的数据值优于对照组。观察组患者血清核因子κ B受体激活剂配体水平、骨保护素水平、用力肺活量1水平及用力肺活量1/用力肺活量值均显著高于对照组(p<0.05)。不良反应评价方面,观察组治疗期间不良反应发生率低于对照组(p<0.05)。阿仑膦酸钠联合α -钙化醇可在一定程度上提高慢性阻塞性肺疾病和骨质疏松症患者的临床疗效,并对血清核因子κ B配体受体激活剂、骨保护素水平和肺功能有较好的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
2 months
期刊介绍: The Indian Journal of Pharmaceutical Sciences (IJPS) is a bi-monthly Journal, which publishes original research work that contributes significantly to further the scientific knowledge in Pharmaceutical Sciences (Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Pharmacology and Therapeutics, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics, Drug Information, Patient Counselling, Adverse Drug Reactions Monitoring, Medication Errors, Medication Optimization, Medication Therapy Management, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest). The Journal publishes original research work either as a Full Research Paper or as a Short Communication. Review Articles on current topics in Pharmaceutical Sciences are also considered for publication by the Journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信